Tendon Repair News
-
Acumed Acquires Exsomed to Enhance Its Portfolio of Upper Extremity Solutions
Acumed, a Colson Medical - Marmon - Berkshire Hathaway company, is excited to announce the acquisition of ExsoMed, a provider of innovative solutions for hand surgery. The addition of ExsoMed, whose products support an intramedullary approach to treating hand fractures, enhances Acumed’s comprehensive portfolio of upper extremity solutions for simple to complex injuries. Acumed, a Colson ...
-
Amgen And Lance Bass Partner To Encourage People To Do A `Double Take` To Recognize The Early Signs Of Psoriatic Arthritis
THOUSAND OAKS, Calif., May 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Otezla® (apremilast) have partnered with pop icon and entrepreneur Lance Bass, for the Double Take campaign to empower people to take action when it comes to psoriatic arthritis. As a singer, dancer and entertainer, Bass understands the importance of staying in tune with your body. Through the campaign, he has created ...
By Amgen Inc.
-
Replicel Announces Extension to Private Placement
Replicel Life Sciences Inc. (the “Company” or “Replicel”) announces that the TSX Venture Exchange (the “Exchange”) has granted a thirty (30) day extension to the Company for completion of its non-brokered private placement (the “Offering”), previously announced in its News Release of March 21, 2022. The terms of the Private Placement provide for ...
-
Biorez Adds Two Esteemed Surgeons to its Scientific Advisory Board
Biorez Inc., a start-up advancing tendon and ligament healing with its proprietary BioBrace Technology, announced today that the company is expanding its scientific advisory board to include Drs. Joseph Burns of Atlanta and Deryk G. Jones of New Orleans. “Drs. Burns and Jones are both accomplished surgeons, thought leaders, and published researchers in sports medicine, and we are ...
By Biorez Inc.
-
RepliCel Announces Non-brokered Private Placement
RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing novel, next-generation injection technologies as well as regenerative medicine products in aesthetics and orthopedics, is pleased to announce a non-brokered private placement financing (the “Offering”) of up to 8,333,333 units (each, a ...
-
RepliCel Announces Material Patent Milestones
RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing novel, next-generation injection technologies as well as regenerative medicine products in aesthetics and orthopedics, is pleased to announce the filing of a new patent application covering novel aspects of the DermaPrecise™ product portfolio as well ...
-
RepliCel Closed Final Tranche of Strategic Investment Commitment
RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it has closed the final tranche of the investment by MainPointe Pharmaceuticals (“MainPointe”) as outlined in the share purchase agreement signed by the ...
-
RepliCel Terminates License Agreement with Shiseido
RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, announced today that the dispute between Shiseido and RepliCel has led to the Company electing to terminate the license agreement with Shiseido. The Company’s decision is a legal step in its ...
-
RepliCel Ships DermaPrecise Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing
RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, announced today it has shipped DermaPrecise Injector prototypes and consumables to an independent laboratory in Germany to conduct validation studies of injection parameters in various types of ...
-
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it’s clinical advisory team has completed the primary design of the next-phase clinical study of its skin rejuvenation product, RCS-01, to be conducted as part of ...
-
Biorez Appoints Jeff Grebner as Director of Clinical Affairs
Biorez Inc., a New Haven, late-stage start-up advancing tendon and ligament healing, today announced the appointment of Jeff Grebner as Director of Clinical Affairs. Grebner joins the Biorez team at an opportune time as the company hits key clinical and procedural milestones with its proprietary BioBrace Implant technology in 2021. “Jeff is a thoughtful clinical leader with ...
By Biorez Inc.
-
Biorez Awarded Four New Patents Related to Its Proprietary BioBrace Technology
Biorez Inc., a New Haven start-up advancing tendon and ligament healing, announced today that four key utility patents were issued by the United States Patent and Trademark Office between July and September 2021. The four new patents relate to Biorez’s proprietary BioBrace Implant, which is a biocomposite soft tissue scaffold intended to reinforce soft tissue repair, and act as a ...
By Biorez Inc.
-
Microlyte SURGICAL Associated with Positive Outcomes in Prospective Clinical Case Series in Patients at Risk for Surgical Site Infection
Imbed Biosciences, Inc. (Imbed), a privately held biotech company emerging as a leader in advanced wound care, announced today the results of a prospective clinical evaluation of its next-generation wound Matrix, Microlyte® SURGICAL, in diabetic patients undergoing foot and ankle surgery who would ordinarily be at risk of a surgical site infection. Results will be published in the October ...
-
InGeneron Reports First-In-Human Microscopic Evidence of Adult Tendon Regeneration Following Autologous Stem Cell Treatment
InGeneron, Inc., a clinical stage regenerative medicine and cell therapy company, today announced the publication of the first-in-human comprehensive immunohistochemical evaluation of adult tendon repair following the local injection of fresh, uncultured, unmodified, autologous, adipose derived regenerative cells (UA-ADRCs). This newly-released research paper, titled “First ...
-
Biorez Wins Major Award at Top Sports Medicine Conference for Its BioBrace Implant
Biorez Inc., a New Haven start-up advancing tendon and ligament healing, announced today that its proprietary, and recently FDA-cleared BioBrace Implant, received the AOSSM ACE Award for ‘Accelerating the Cutting Edge.’ The award was given at the annual meeting of the American Orthopaedic Society for Sports Medicine (AOSSM), held jointly with the Arthroscopy Association of ...
By Biorez Inc.
-
RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Cell Therapies
RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has submitted its application to Japan’s Ministry of Health, Labour, and Welfare (MHLW) for approval to manufacture the Company’s RCT-01 cell therapy for ...
-
Biorez Announces FDA 510(k) Clearance of Its Proprietary BioBrace Implant Technology
Biorez Inc., a New Haven start-up advancing tendon and ligament healing, announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for two sizes of its BioBrace Implant. This new biocomposite soft tissue scaffold is intended to be used in a broad range of surgical procedures to reinforce soft tissue where weakness exists, and can be used with ...
By Biorez Inc.
-
Biorez Announces David Hook as Vice President of Sales as it Prepares for BioBrace Commercialization
Biorez Inc., a New Haven late-stage start-up advancing tendon and ligament healing, today announced the appointment of David Hook as Vice President of Sales. Mr. Hook joins the Biorez team at an opportune time as the company approaches an expected 510(k) clearance, and limited commercial launch of its proprietary BioBrace Implant technology in the first half of 2021. “David is a ...
By Biorez Inc.
-
Biorez Announces the Appointment of Nicholas Pachuda to Expanded Board of Directors
Biorez Inc., a New Haven start-up advancing tendon and ligament healing, today announced that medical device industry veteran, Nicholas Pachuda, has been appointed to its Board of Directors. A Podiatric Surgeon by training, Dr. Pachuda has spent the last 20 years in commercial leadership positions for DePuy Synthes (a Johnson & Johnson company), Arthrex, and a number of startups ...
By Biorez Inc.
-
CoNextions Inc. Announces First Patient Treated with Coronet Soft Tissue Fixation System, a Revolutionary Tenodesis Product
CoNextions Inc. (www.conextionsmed.com), an innovator in tendon repair, announced today the first patient has been treated with the Coronet Soft Tissue Fixation System in a Kidner procedure. The Kidner procedure is the most common surgical treatment for a painful accessory navicular bone that causes foot/tendon pain. The Coronet Soft Tissue Fixation Systems is a tenodesis device intended for the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you